Linperlisib
- Generic Name
- Linperlisib
- Drug Type
- Small Molecule
- Chemical Formula
- C28H37FN6O5S
- CAS Number
- 1702816-75-8
- Unique Ingredient Identifier
- 05HYK3CV9N
- Indication
用于既往接受过至少两种系统性治疗的复发或难治滤泡性淋巴瘤成人患者。
FDA Approves Yingli Pharma's Phase III Trial for Novel PTCL Treatment Linperlisib
• Yingli Pharma has received FDA clearance to initiate a global Phase III registration trial of linperlisib for relapsed/refractory peripheral T-cell lymphoma (PTCL) following a successful End-of-Phase II meeting.
• The pivotal study, set to begin in Q2 2025, will compare linperlisib against physician's choice of standard care in patients who have undergone previous systemic therapies, with enrollment across multiple countries.
• Linperlisib, a selective PI3Kδ inhibitor, has demonstrated promising efficacy in over 165 PTCL patients across China, US, and Europe, with high response rates and a well-tolerated safety profile in over 6,000 treated patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath